Quantity of eligible individuals: CDEC mentioned the uncertainty in the amount of individuals with moderately significant to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some sufferers who are categorized as getting mod